http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-078733-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| filingDate | 2010-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-078733-A1 |
| titleOfInvention | FUSIONED HETEROCICLICAL COMPOUNDS AS MODULATORS OF THE OREXINE RECEIVER |
| abstract | Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseases, disorders and conditions mediated by orexin activity, such as insomnia. Claim 1: A chemical entity that is a compound of Formula (1): wherein: n is 0-1; R1 is a member selected from the group consisting of: A) phenyl substituted or unsubstituted with one or two Ra members, and substituted in the ortho position with Rb; Ra is independently selected from the group consisting of: halo, -C1-4 alkyl and -C1-4 alkoxy, wherein two adjacent Ra members can be joined to form a six-membered aromatic ring; Rb is a member selected from the group consisting of: a) halo, -C1-4 alkoxy, -CF3 or -CF2CHF2; b) a 5-membered heteroaryl ring containing an oxygen or sulfur member; c) a 5-6 membered heteroaryl ring containing one to three nitrogen members, optionally, containing an oxygen member, substituted or unsubstituted with halo, -C1-4 alkyl, tetrahydropyran-2-yl, or - N (CH3) 2; and d) phenyl substituted or unsubstituted with -F or -CH3; B) pyridine substituted or unsubstituted with one or two members Rc and substituted with Rd, where Rd is placed adjacent to the junction point by R1; Rc is a member independently selected from the group consisting of: -C1-4 alkyl, -CF3 and -C1-4 alkoxy; Rd is a member selected from the group consisting of: a) a 5-6 membered heteroaryl ring selected from the group consisting of: 1H-1,2,3-triazol-1-yl, 2H-1,2,3- triazol-2-yl, 1H-pyrazol-3-yl and 6-methyl-pyridin-2-yl; and b) -CF3, -Br or -C1-4 alkoxy; C) a 6-membered heteroaryl ring selected from the group consisting of: pyrimidin-yl or pyrazin-yl substituted or unsubstituted with a member independently selected from -CH3, -OCH3 or phenyl; D) a 5-membered heteroaryl ring selected from the group consisting of: 2-methyl-1,3-thiazol-yl, 5-methyl-isoxazol-4-yl, 2H-pyrazol-3-yl, 1H-pyrazole-4 -yl, isoxazolyl and 1,3-oxazol-4-yl, each substituted with phenyl substituted or unsubstituted with -F or -CI; and E) 3-methylfuran-2-yl, 9H-fluorene, 9H-fluoren-9-one, 3,5'-biisoxazole, [3-methyl-5- (4-methyl-1,2,3-thiadiazole- 5-iI) isoxazol-4-iI] or naphthyridine; R2 is a member selected from the group consisting of: A) a 6-membered heteroaryl ring containing two nitrogen members substituted or unsubstituted with one or more members independently selected from the group consisting of: halo, -C1-4 alkyl , -C1-4, -CF3, -NH2, -NHCH3 alkoxy, -N (C1-4) 1-2 alkyl, cyclopropyl-NH and phenyl; B) pyridine substituted or unsubstituted with one or two members independently selected from the group consisting of: -C1-4 alkyl, -N (C1-4 alkyl) 2 and -CF3; and C) quinoxalin-2-yl, benzooxazol-2-yl or 5-chloro-1,3-benzoxazole; and pharmaceutically acceptable salts of the compounds of Formula 1. |
| priorityDate | 2009-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.